ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona
CD
CHU de Besançon at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
CHU de Besançon takes part in 4 sessions at ESMO 2026 in Madrid. Its work spans breast and digestive cancers, with studies of biomarkers and treatment outcomes, alongside early melanoma. One study assesses markers that may help predict benefit from chemotherapy after pancreatic cancer surgery.
| Organization | ESMO 2026 Attendance |
|---|---|
CD CHU de Besançon Besançon, France | |
Regional university hospital in Besançon, eastern France. | Poster Sat Oct 24 12:00–12:45 Beyond clinical risk: Real-world insights from genomic profiling in early breast cancer – the FREDO-ODX study Breast cancerBiomarkers & precision oncology Poster Sun Oct 25 12:00–12:45 Poster Sun Oct 25 12:00–12:45 Stromal HSP47 and membranous β-catenin as prognostic and predictive biomarkers of adjuvant chemotherapy benefit in pancreatic ductal adenocarcinoma: Development and independent validation Gastrointestinal cancersBiomarkers & precision oncology Chair Sun Oct 25 14:45–16:00 More cures in early melanoma Melanoma & skin cancers Talk Sun Oct 25 14:45–14:50 Presentation of case/condition Melanoma & skin cancers |
Find decision makers at CHU de Besançon
Tell us what you sell and we’ll find the people at CHU de Besançon most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction